Loading the section…

GDRX: financial statements from SEC — TradeAlmanac

GDRX

GoodRx Holdings, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Revenue	194M	196M	203M	203M	195M	201M
Cost of revenue	20M	13M	13M	13M	12M	12M
Research and development	30M	31M	30M	31M	30M	31M
Selling, general and administrative	27M	32M	28M	30M	26M	28M
Operating expenses	180M	181M	176M	180M	175M	181M
Operating income	14M	15M	27M	23M	20M	20M
Interest expense	—	—	—	—	—	15M
Pre-tax income	6M	6M	20M	17M	8M	12M
Income tax	4M	5M	7M	6M	4M	5M
Net income	1M	1M	13M	11M	4M	7M
Earnings per share	0.00	0.00	0.04	0.03	0.01	0.02
Earnings per share, diluted	0.00	0.00	0.04	0.03	0.01	0.02
Weighted average shares	341M	347M	357M	379M	380M	376M
Weighted average shares, diluted	341M	348M	357M	380M	389M	385M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	236M	262M	274M	281M	301M	448M	424M	525M
Receivables	233M	236M	204M

Cash flow

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Operating cash flow	12M	—	—	9M	—	—
Depreciation and amortisation	22M	21M	20M	21M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator